C-Biotech
The computed 12-month bankruptcy probability of C-Biotech is 3.4% (average). The 2024 annual accounts show equity of €195k and a net result of €-629k. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €195k |
| Net result | €-629k |
| Staff (FTE) | 1.8 |
| Active | 3 yrs |
Fragile profile — watch health in particular.
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Starter.
See plans →| Fiscal year | 2024 |
|---|---|
| Revenue | €97k |
| EBITDA | €-544k |
| Net profit | €-629k |
| Cash flow | €-591k |
| Staff costs | €107k |
| Income taxes | — |
| Dividends | — |
| Total assets | €2.67M |
| Equity | €195k |
| Debt | €2.48M |
| of which ≤ 1y | €2.35M |
| of which > 1y | — |
| Working capital | €-821k |
| Employees (FTE) | 1.8 |
| 2024 | |
|---|---|
| Current ratio | 0.65 |
| Quick ratio | 0.45 |
| Working capital ratio | -30.7% |
| Solvency | 7.3% |
| Debt / equity | 12.72 |
| Long-term debt ratio | — |
| Interest coverage | -11.58 |
| Gross margin | -528.7% |
| Net margin | -647.2% |
| ROA | -23.5% |
| ROE | -322.8% |
| EBITDA margin | -560.2% |
| Days sales outstanding | 294d |
| Days payable outstanding | 262d |
| Inventory turnover | 1.27 |
| Days inventory (DSI) | 288d |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet — Assets | ||
| TOTAL ASSETS | 20/58 | €2.67M |
| Fixed assets | 21/28 | €991k |
| Formation expenses | 20 | €152k |
| Intangible fixed assets | 21 | €375k |
| Tangible fixed assets | 22/27 | €151k |
| Financial fixed assets | 28 | €466k |
| Current assets | 29/58 | €1.53M |
| Stocks & contracts in progress | 3 | €482k |
| Amounts receivable within one year | 40/41 | €431k |
| Cash & bank | 54/58 | €616k |
| Balance sheet — Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2.67M |
| Equity | 10/15 | €195k |
| Contributions / capital | 10/11 | €1.25M |
| Accumulated profits (losses) | 14 | €-1.06M |
| Amounts payable | 17/49 | €2.48M |
| Amounts payable within one year | 42/48 | €2.35M |
| Trade debts payable within one year | 44 | €439k |
| Income statement | ||
| Turnover | 70 | €97k |
| Gross operating margin | 9900 | €-436k |
| Operating result | 9901 | €-582k |
| Financial income | 75 | €3 |
| Financial charges | 65 | €47k |
| Result before taxes | 9903 | €-629k |
| Net result for the period | 9904 | €-629k |
| Result to be appropriated | 9905 | €-629k |
| NACE primary | 39000 |
| Legal form | Private limited company(610) |
| Incorporation | 16-12-2022 |
| Status | Active |
| Postal code | 9140 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates — not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 46025B1190/00E026 | Flanders | 5.3 ha | 1 · 2,811 m² | 4.5 m |
A single timeline of everything that happened to this company — publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
06-06-2025 1 director appointed, 1 resigning
- BERT WEEMAES — Bestuurder
- Nova LaGa BV — Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": null,
"reason": "de_plein_droit_dissolution",
"subkind": null,
"via_org": {
"kbo": "0563.544.462",
"name": "Nova LaGa BV",
"address": "Justitiestraat 51, 2018 Antwerpen",
"country": "BE",
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De algemene vergadering neemt kennis van het ontslag uit het bestuursmandaat, dit met ingang vanaf heden, uitgeoefend door Nova LaGa BV, KBO nummer 0563.544.462, met vennootschapszetel te 2018 Antwerpen, Justitiestraat 51 met vaste vertegenwoordiger mevrouw Gacoin Laurence;",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "bestuurder",
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De Aandeelhouders beslissen met eenparigheid van stemmen tot het verlenen van kwijting aan de ontslagnemende bestuurder voor de uitoefening van haar mandaat.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "BERT WEEMAES",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "De Aandeelhouders benoemen, met onmiddellijke ingang vanaf heden, als nieuwe bestuurder van de Vennootschap BERT WEEMAES, besloten vennootschap, KBO nummer 0537.167.687, met vennootschapszetel te 2000 Antwerpen, Entrepotkaai 2 bus 504, met vaste vertegenwoordiger de heer Bert Weemaes;",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-06-06",
"filing_date": "2025-05-28",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2025-04-01",
"unanimous": null
},
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-04-01",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0794.909.852",
"name_full": "C-Biotech",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Arianne Vervliet",
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}04-07-2024 Capital increase of €1,252,629.76 to €602,649.14
- €-649.980,62 → €602.649,14
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 602649.14,
"delta_eur": 1252629.76,
"before_eur": -649980.62,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "org",
"name": "FINO",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "schuldvordering",
"n_shares_subscribed": 25,
"contribution_amount_eur": 1252629.76
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 25,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "schuldvordering_inbreng",
"paid_up_delta_eur": 1252629.76,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Els DE BLOCK",
"firm_city": null,
"firm_name": "Els De Block en Tim Vandersteen, geassocieerde notarissen",
"office_city": "Temse",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2024-07-04",
"filing_date": "2024-07-02",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-06-24",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "VGD Bedrijfsrevisoren BV",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Bart Roose"
},
"subject_company": {
"kbo": "0794.909.852",
"name_full": "C-Biotech",
"legal_form": "B.V.",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"geco\u00F6rdineerde statuten",
"verslag bestuursorgaan",
"verslag revisor"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "org",
"name": "FINO",
"role": "aandeelhouder",
"n_shares": 75,
"share_class": null
},
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "Verstraete Frederik",
"role": "aandeelhouder",
"n_shares": 50,
"share_class": null
}
],
"share_classes_after": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | C-Biotech |